Scientists reprogram Patients' own cells to hunt prostate cancer
NCT ID NCT01140373
Summary
This early-stage study is testing the safety of a new personalized treatment for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. Doctors take a patient's own immune cells (T cells), genetically modify them in a lab to better recognize prostate cancer, and then infuse them back into the patient. The main goal is to see if this approach is safe and what side effects it might cause, while also looking for early signs that it could help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.